Daclatasvir, asunaprevir and beclabuvir;
Ximency (TN)

(Daclatasvir dihydrochloride [DR:D10105] | Daclatasvir [DR:D10065]), Asunaprevir [DR:D10093], (Beclabuvir hydrochloride [DR:D10611] | Beclabuvir [DR:D10610])

Antiviral

Daclatasvir is a substrate of CYP3A4 and P-glycoprotein (P-gp) , and it is an inhibitor of the following transporters: P-gp, OATP1B1, OATP1B3 and BCRP.
Asunaprevir is a substrate of CYP3A, P-gp and OATP1B1, and it is an inhibitor of CYP2D6, OATP1B1, OATP1B3 and P-gp and a inducer of CYP3A4.
Beclabuvir is a substrate of CYP3A, P-gp and BCRP, and it is an inhibitor of P-gp, BCRP, OATP1B1 and OATP1B3 and a inducer of CYP3A4.

HCV NS3/4A protease [KO:K22273 K22274]
HCV NS5A [KO:K22275]
HCV NS5B [KO:K22472]

Enzyme: CYP3A [HSA:1576 1577 1551]
Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599]

CYP induction: CYP3A4 [HSA:1576]
Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
DDI search